Taken together, the KDE was well tolerated, attenuated anorexia, altered systemic metabolism, attenuated indices of tumor burden, and reduced skeletal muscle atrophy without changing circulating IGF‐1 and insulin levels, illustrating a unique and multifaceted anti‐CACS therapy. This evidence concerns the gene IGF1 and neoplasm.